Compare TLS & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TLS | ALT |
|---|---|---|
| Founded | 1969 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 463.8M | 501.9M |
| IPO Year | 2020 | N/A |
| Metric | TLS | ALT |
|---|---|---|
| Price | $5.76 | $5.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $7.75 | ★ $16.33 |
| AVG Volume (30 Days) | 1.1M | ★ 3.3M |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $144,400,000.00 | $20,000.00 |
| Revenue This Year | $47.80 | N/A |
| Revenue Next Year | $26.19 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 17.44 | N/A |
| 52 Week Low | $1.83 | $2.90 |
| 52 Week High | $8.36 | $10.88 |
| Indicator | TLS | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 41.42 | 74.79 |
| Support Level | $5.68 | $4.40 |
| Resistance Level | $5.99 | $4.75 |
| Average True Range (ATR) | 0.55 | 0.29 |
| MACD | -0.04 | 0.10 |
| Stochastic Oscillator | 13.26 | 92.19 |
Telos Corp offers technologically forwarded, software-based security solutions that empower and protect the world's security-conscious organizations against rapidly evolving, sophisticated, and pervasive threats. Its business has two reportable and operating segments namely Security Solutions and Secure Networks. The Security Solutions segment focuses on cybersecurity, cloud, and identity solutions, and the Secure Networks focuses on enterprise security. The company derives maximum revenue from the Security Solutions segment.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.